Guerbet S.A.
GUERF
Other OTC22.25
USD
- -
- -
Return %
Stock
S&P500
1Y
- -
19.99
3Y
- -
69.40
5Y
- -
72.03
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- David Hale
- Full Time Employees
- 2,839
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 15, rue des Vanesses Villepinte France 93420
- IPO Date
- Apr 3, 2017
- Website
- guerbet.com
- Similar Companies
- Business
- Guerbet SA develops, manufactures and markets contrast agents, delivery systems, medical devices and related solutions for diagnostic and interventional radiology. The company offers a comprehensive portfolio of products including non-ionic iodinated contrast agents such as Optiray, Xenetix, Telebrix Gastro and Conray; MRI contrast agents such as Dotarem and Artirem; barium-based products including Micropaque/Microtrast; interventional radiology products such as Lipiodol ethyl esters of iodinated fatty acids, Vectorio mixing and injection system, Patent Blue V dye, Axessio peripheral micro guidewire, SeQure and DraKon microcatheters; digital solutions including Contrast&Care for injection management, Dose&Care for X-ray dose management, icobrain AI for brain structure quantification and OptiProtect services; as well as prefilled syringes, injectors, accessories and consumables for MRI, CT and Cath Lab procedures. Guerbet operates globally with manufacturing facilities in France, Ireland, Canada, Macedonia, the United States and Brazil, serving markets in diagnostic imaging for MRI/CT/Cath Lab, interventional imaging and theranostics, with target customers including hospitals, radiology centers and healthcare providers in cardiovascular, neurology, oncology and other therapeutic areas. Founded in 1926 and headquartered in Villepinte, France, the company employs over 2,700 people worldwide and invests approximately 10% of revenues in research and development through innovation centers in France and the United States. Recent developments include a strategic partnership with Nuclidium on May 22, 2024, to advance targeted copper-based radiotheranostics; marketing authorization approval for Elucirem (Gadopiclenol) in the European Union on December 11, 2023; 510(k) clearance for DraKon microcatheter on June 16, 2023; a win in the PI-CAI Grand Challenge for prostate cancer detection on July 17, 2023; sale of Accurate Medical microcatheter assets to Argon Medical in February 2025; and strong 2024 financial performance with 20.5% growth in the Americas, expansion of Elucirem in the US, Germany, UK, France and Switzerland, and R&D progress on Lipiojoint designated as a US FDA Breakthrough Device for knee osteoarthritis treatment.